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Previous studies have shown that human serum, guinea pig and human red cells,
and human white cells contain low and high M, substances that induce gonococcal
strains to become serum resistant (1-4) and change lipooligosaccharide (LOS)' pat-
tern (5, 6) . In more recent studies, the same investigators have shown that the low
Mr substance in- blood is cytidine monophospho-N-acetylneuraminic acid (CMP-
NANA) or a related compound (7, 8) . These studies suggest that in vivo, sufficient
concentrations ofCMP-NANA might induce serum resistance by sialylation of LOS.
Because gonococci are not able to synthesize CMP-NANA and it is not present in
the usual media, previous in vitro studies of gonococcal LOS may have dealt with
different LOS structures than those that occur in vivo .
Each gonococcal strain makes multiple types of LOS (9-11), and the physical (Mr)
and antigenic heterogeneity of a strain's LOS reflects physicochemical differences
in their glycan moieties (10, 12). mAbs 3F11 and 06B4 identify epitopes on menin-
gococcal and gonococcal LOS that are immunochemically similar to Galo1-4G1cNAc-
containing molecules present in human erythrocytes andon other human cells (13) .
These epitopes are conserved on gonococcal LOS (11, 14) and are variably expressed
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on the LOS of meningococci and Neisseria lactamica (15) . It is possible that
Gal#1-4GIcNAc structures are potential targets of LOS sialylation, because these
same structures also often are sialylated in mammalian glycoproteins (16) and in
some glycosphingolipids (17) .
In this report, we identify the LOS component and the epitope that is sialylated
by CMP-NANA, show the effect of CMP-NANA on the antigenicity of these mole-
cules, and show that LOS of gonococci incubated in human neutrophils (polymor-
phonuclear leukocytes [PMNs]) may be similarly sialylated .
Materials and Methods
Bacterial Strains. N. gonorrhoeae strains F62, DOV and WR213 were kindly provided by
Dr. Herman Schneider (Walter Reed Army Institute of Research, Washington, DC) (10, 11,
18). Strain 1291 and its pyocin-selected mutants 1291A and 1291C (19), strain 8551 (20), and
strains 15253 and 15433, kindly provided by Dr. Peter A. Rice (Boston University, Boston,
MA), have been described previously. Strains 15253 and 15433 have LOS components that
are all <4.0 kD and do not bind mAbs 3F11 and 06B4 (21) . A colony blot assay was done
with mAb 3F11 to select from strains 15253 and 15433 population variants that made higher
M,- LOS (22) .
LOS and Outer Membrane Complex (OMC) . LOS (18) and OMC (23) antigens were pre-
pared as described.
mAbs. The preparation and characterization of mouse anti-LOS mAbs 3F11 (11, 13, 14),
06B4 (11, 13), 1-1-M (11), 6137 (19), and 4C4 (24) have been described. mAb 2C3 was gener-
ated after immunization of mice with intact N. gonorrhoeae ; it is an IgG2b isotype . It recog-
nizes a surface-exposed H.8 protein epitope on >90% of gonococcal strains and is highly
specific for pathogenic Neisseria (25, 26). mAbs were kindly provided by Dr. Peter A. Rice
(2C3 ; Boston University), Dr. Julie Westerink (6B7 and 4C4; State University of New York
at Buffalo, Buffalo, NY), Dr. Shinzo Isojima (H6-3C4; Hyogo Medical College, Hyogo, Japan),
and Dr. Senitroh Hakomori (1139 and NUH2; The Biomembrane Institute, Seattle, WA).
mAb IB9 recognizes NeuNAca2-6Ga1 residues on lacto series gangliosides and on glycopro-
teins (27) . mAb NUH2 recognizes an epitope having two identical NeuNAca2-3Galo1
-4G1cNAc structures, 01-3 and (31-6 linked to Galol-4GIcNAc (28, 29). mAb H6-3C4
is a humanmAb that immobilizes human sperm and recognizes repetitive N-acetyllactosamine
structures that are either sialylated or nonsialylated (28) . mAb MC-813-70 was obtained from
the Developmental Studies Hybridoma Bank, Johns Hopkins University, Baltimore, MD;
it recognizes NeuNAca2-3Galf31-3Ga1NAcol-R found on mouse stage-specific embryonic
antigen 4 (30) . Each of the mAbs was tested in aTLC immunostaining assay (31) with mam-
malian glycosphingolipids to assure that the appropriate activity was present.
SDS-PAGEand Immunoblotting. LOS samples were separated through polyacrylamide slab
gels by the method ofLaemmli (32) . In one experiment, the LOS of strain 1291 was separated
using a tricine SDS-PAGE gel system in order to improve resolution of individual compo-
nents (33) . Immunoblotting (11) and silver staining (34) were done as described previously.
The M,_s of LOS components were estimated by reference to the LOS of meningococcal
strain 8032, which has six LOS components with different M,s designated as 5.4, 5.1, 4.5,
4.0, 3.6, and 3.2 (24) .
Solid Phase Radioimmunoassay (SPRIA). SPRIAwas performed as described previously (11,
35). Stock solutions of LOSs or OMCs were diluted in Dulbecco PBS modified to contain
50 mM MgC12, and 50 mg/ml solution of the LOS or OMC was used to sensitize polyvinyl
microtiter wells. In some assays, whole organisms were used as antigens (36) .
Neuraminidase Treatment of Immobilized LOS. We used two different preparations of neur-
aminidase for these studies. For initial SPRIA studies of the effect ofneuraminidase on LOS
antigens, we used Clostridium perfringens neuraminidase (type V; Sigma Chemical, St . Louis,
MO). For confirmation of results, we used a purified streptococcal neuraminidase (Genzyme,
Boston, MA). This preparation contains other relevant glycosidases at levels <0.033% by
activity.
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After sensitization of polyvinyl microtiter wells with LOS (25 Al of 25-lcg/ml concentra-
tion) for 1 h, the wells were washed with PBS, pH 6, and then 25 Wl of various concentrations
of neuraminidase (0.01-10 mU/ml, diluted in PBS, pH 6) were added to the wells . PBS was
added to duplicate wells as a negative control . After incubation for 2 h at 37oC, the enzyme
or buffer was removed, and the wells were treated with filler to block nonspecific binding .
Mouse mAb and ' 1 'I-labeled goat anti-mouse IgG or IgM were added as described previ-
ously (11) .
Growth of Organisms in Media with CMP-NANA . N. gonorrhoeae strain 1291, and its pyocin-
resistant mutant strains 1291A and 1291C, were grown overnight on GC agar base (Difco
Laboratories Inc ., Detroit, MI) containing 1% supplement (37), then used to inoculate the
defined liquid GC media of Morse and Bartenstein (38) or liquid or solid GC media (18,
37) with or without CMP-NANA (Sigma Chemical Co.) (8) . Organisms were removed at
various time points during growth . Proteinase K (Sigma Chemical Co.) lysates were pre-
pared from these samples (39) for SDS-PAGE, silver staining, and immunoblot analyses. For
strains 1291 and F62, we found that concentrations ofCMP-NANA >50 /~g/ml in both media
resulted in maximal modification of the mAb-defined epitopes on the 4.5-kD LOS compo-
nent . For strains grown on solid GC agar, organisms were collected, washed once in PBS,
and diluted to a concentration of -0.2 x 10'' CFU/ml . A 0.5-ml volume of diluted organisms
was mixed with an equal volume of a 500 -1~g/ml solution of CMP-NANA in PBS, pH 7.4,
and spread on GC agar plates . After the liquid evaporated, the plates were incubated in 5%
C02 for 18 h at 37oC . Organisms were removed from the surface of the medium and sus-
pended in Dulbecco PBS (OD, ;2 = 0.2) for whole cell SPRIA (36) or in SDS-PAGE sample
buffer for treatment with proteinase K (39) .
Immunoelectronmicroscopy (IEM). For in vitro studies, IEM was as described (40) on N. gonor-
rhoeae strain 1291 that had been grown for 6 h in defined medium with and without 100 Ag/ml
CMP-NANA . Before IEM, an aliquot ofthese cells was tested by SDS-PAGE and electroblot
studies to insure that CMP-NANA had reacted with the LOS. The specimen was suspended
in 1-2% glutaraldehyde and 0.1 M cacodylate buffer, pH 7.4, then incubated for 2 h, then
embedded in LR-white embedding solution (London Resin Co ., Ltd ., London, UK) as de-
scribed (41). Sections were incubated sequentially with various combinations of mAb 06134
(10 pg/ml), colloidal gold conjugated to a goat anti-mouse IgM antibody (Janssen Biotech-
nology, Piscataway, NJ), and neuraminidase (2 .0 U/ml, type VI ; Sigma Chemical Co. ; 1 h
at 37 °C) . The sections were washed between each step . The specimens were examined with
a transmission electron microscope (lA ; Siemens Elmskop) at 80-kV accelerating voltage .
Strain 1291 also was incubated with human PMN, and LOS epitope expression was exam-
ined by IEM. Freshly obtained whole human blood was collected in siliconized, heparinized
blood tubes . Dextran in 0.15 M NaCl was added to a final concentration of 1% . After sedimen-
tation for 45-60 min at room temperature, the upper plasma layer was transferred to a
siliconized tube and 2 vol of0.87% ammonium chloride was added to remove residual erythro-
cytes . The PMNs were sedimented at 100 g for 10 min and washed twice with sterile Dul-
becco's PBS without Cal' or Mg2., but containing 0.1% glucose, pH 7.4. N. gonorrhoeae strain
1291 (p - , op`) was grown for 18 h on GC agar medium (18), suspended in PBS (013,;o =
0.2, -10' cells/ml), added to suspended PMNs at a ratio of 10 gonococci/1 PMN, and then
gently rotated at 37°C . PMNs were fixed either before addition of strain 1291 or at various
times up to 1 h after addition of 1291 . Glutaraldehyde was added to 1% and the fixed speci-
mens were kept at VC until IEM studies were done as described above .
Treatment of Purled Gonococcal Strain F62 LOS with a 0.5% Triton X-100 Extract of the Or-
ganisms. Gonococcal strain F62 was added to liquid GC medium (18) to an OD62o of 0.1
and grown for 4 h at 37oC . Organisms were pelleted and washed once with PBS . The pelleted
organisms were suspended in 0.5% Triton X-100, the suspension was sonicated (Branson Sonic
Power Co., Danbury, CT) for 15 s, then centrifuged in a microfuge . The supernatant was
collected and stored at -20°C until further use . The reaction mixture consisted of 20 AI
of F62 LOS (1 mg/ml in distilled water), 10,u10.5M sodium phosphate buffer (pH 6.8), 10 Al
cytidine 5'-monophospho-[' 4C]-N-acetylneuraminic acid (0.25 pCi, -0.6 fag ; Amersham
Corp., Arlington Heights, IL), and 50 Al of 0.5% Triton X-100 extract (N25 ltg protein) .
For negative controls, 50 Al of 0.5% Triton X-100 buffer was added in place of the extract .
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The samples were added to microfuge tubes and incubated for 14 h at 37°C . After incuba-
tion, 50 Id of SDS-PAGE gel sample buffer (see SDS-PAGE section) was added, the samples
were incubated at 37°C for 10 min, then the samples were run in SDS-PAGE . The gel was
silver stained (34), dried, then incubated in Kodak X-Omatic cassettes with regular inten-
sifying screens and Kodak X-Omat film (Eastman Kodak Co ., Rochester, NY) at -70°C
for 7 d . The exposed film was processed for viewing .
Treatment of Purified Gonococcal LOS with a2-3 and0-6Sialyltransferases (STases). Rat liver
CMP-NANA:Ga1(31-4GlcNAca2-"6 STase and porcine submaxillary gland CMP-
NANA:oGala2-+3 STase enzymes (Genzyme) (no detectable a2-6 STase activity in the a2-3
STase and no detectable a2-3 STase activity in the a2-6 STase, according to the manufac-
turer) were assayed with F62 LOS. The reaction mixture for the assay consisted of 10 pl of
a 4-mg/ml suspension ofF62 LOS, 20 pl BSA (2.5 mg/ml), 10 PI detergent buffer (2 .5 % Triton
X-100 in 0.25 M sodium cacodylate, pH 6.0), 5 ul cytidine 5'-monophospho-[ ' 4C]-N-
acetylneuraminic acid (0.125 p.Ci, -0.3 ug; Amersharn Corp.), and 5 lil enzyme (120-170
mU/ml) . For negative controls, 5 ul of detergent buffer was added in place of enzyme ; for
positive controls, 10 IAl of asialofetuin (0 .8 mg/ml) was added in place of LOS. The samples
were added to microfuge tubes and incubated for 14 h at 37 °C . The samples were run in
SDS-PAGE and the dried gels autoradiographed (8 d) as described above .
Results
Identification ofthe Component Modified by CMP-NANA, To define the LOS compo-
nent that was modified by the addition ofNANA, gonococcal strains 1291 and 1291A
were grown in a defined medium in the presence and absence ofCMP-NANA. Fig.
1 shows the silver-stained tricine SDS-PAGE gel of strain 1291 LOS (lanes a and
b) and the LOS of its pyocin-resistant mutant, strain 1291A (lanes c and d), grown
in the presence (lanes b and d) and absence (lanes aand c) of CMP-NANA. A 4.5-kD
LOS component ofstrain 1291 expresses the 3F11 and 06B4 epitopes, whereas strain
1291A does not have this component (19) . Fig . 1, b, shows the shift in the M, ofthe
4.5-kD band of 1291 to an M,-of -4.9 kD . There was no shift in the major band
of 1291A in the presence ofCMP-NANA (Fig. 1, lane d) . Note that cultures ofstrain
1291A contain a small population of revertant bacteria of the parent 1291 ; this is
seen as lightly stained LOS at the same location as seen with strain 1291 LOS (Fig.
1, lane c) . This band (Fig . 1, lane d) behaves identically to the band of parental 1291
LOS, confirming the ability of the revertants to use the active CMP-NANA in the
medium.
We also tested another pyocin-resistant mutant of strain 1291, 1291C, which, due
to reversion, had approximately equal amounts of 1291 parental strain 4.5-kD LOS
and the 3 .6-kD LOS characteristic of strain 1291 C . When this strain was grown
in the presence of CMP-NANA, only the 4.5-kD band shifted M, (data not shown) .
Electrobiot analysis with mAbs 4C4 and 6B7, which recognize epitopes on the 3.6-
kD LOS of 1291 C, indicated that binding to these epitopes was not modified by
the CMP-NANA. Similar immunoblots with mAb 06B4 showed that it reacted with
the 4.5-kD LOS of 1291 while the 1291 LOS from the CMP-NANA-treated organisms
ran at a higher M, and showed decreased binding of mAb 06B4.
FIGURE 1 . Effect ofCMP-NANAon the migration of gonococcal strains
1291 and 1291A LOS . Proteinase K lysates of strains 1291 (lanes A and
B) and 1291A (lanes C and D) grown in the presence (lanes B and D)
and absence (lanes A and C) of CMP-NANA were separated by tricine
SDS-PAGE then silver stained as described (see Materials and Methods) .
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TABLE I
Expression of mAb-defined LOS Epitopes on CMP-NANA-treated Gonococci
A SPRIA was done using as antigen whole organisms grown on GC agar plates
with CMP-NANA . After antigen sensitization, neuraminidase (Genzyme) in
PBS (pH 6) or PBS alone was added and the plates were incubated for 2 h
at 37°C . The wells then were washed and incubated sequentially with mAb
and secondary antibody (see Materials and Methods) . Data are presented as
the cpm of 1251 secondary antibody bound .
1 The numbers in parentheses indicate the percentage of cpm bound by the
PBS-treated antigen compared with the neuraminidase-treated antigen .
Reversal ofCMP-NANA Modification ofLOSby Treatment with Neuraminidase. We used
a SPRIA to test the expression of an epitope present on the 4.5-kD component of
gonococcal LOS (defined by mAbs 3F11 or 06B4) and an epitope on a higher Mr
component (defined by mAb 1-1-M) . The data in Table I show decreased binding
of mAb 3F11 to each of the three CMP-NANA-treated gonococcal strains . F62 and
DOV LOS from CMP-NANA-treated organisms had similar increases in 3F11 ex-
pression after treatment with neuraminidase. In contrast, the binding of mAb 1-1-M
to the LOS was not decreased by growth in the presence of CMP-NANA, nor was
it modified by treatment with neuraminidase.
Modification ofLOS at Various Times during Growth ofF62 in CMP-NANA . To deter-
mine the rate of the change in CMP-NANA-altered epitope expression, we tested
organisms grown for various times in liquid medium with 500 Fig CMP-NANA/ml.
We used strain F62 because it has two major components of -4.5 and -5.4 kDMr
that are well resolved by SDS-PAGE and because we have mAbs that bind separately
to epitopes in the high M, component (mAb 1-1-M) and to those in the lowMr com-
ponent (mAbs 3F11 and 06B4). The results are shown in Fig. 2 . The loss of the 4.5-
FIGURE 2 . Modification of F62 LOS at various time intervals during
growth in CMP-NANA . Gonococcal strain F62 was grown in GC liquid
media containing 500 tcg/ml CMP-NANA . Samples extracted at 0, 1, 2,
3, and 4 h were treated with proteinase K, then lysates were separated
by SDS-PAGE and one gel was silver stained (A) and a duplicate gel was
electroblotted and probed with mAb 3F11 and 125I-labeled secondary an-
tibody (B) . After autoradiography, the immunoblot shown inBwas probed
with mAb 1-1-M and 125I-labeled secondary antibody (C) . The large ar-
rows point to the 4.5-kD component of F62 LOS that binds mAb 3F11
and is modified by the CMP-NANA (A-C, 0 h), and the small arrows
point to the modified component (A, 1-4 h) . mAb 1-1-M binds to the
higher component .
Strain Neuraminidase
CPM bound
3F11
cpm
with mAb:'
1-1-M
cpm
F62 - 3,841 (16)1 83,443 (100)
F62 + 23,071 76,723
WR213 - 17,839 (31) 77,041 (95)
WR213 + 55,963 81,019
DOV - 9,577 (18) 78,487 (94)
DOV + 51,103 83,053
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kD component (Fig . 2 A, see arrow) was almost complete at 2 h, and this loss was
accompanied by both an increase in the size of the 4.5-kD component and the ap-
pearance of a component higher than the 5.4-kD component . In a subsequent ex-
periment using organisms grown in media with 100 ttg/ml CMP-NANA, the 4.5-kD
component of CMP-NANA-modified LOS migrated just below the 5 .4-kD compo-
nent (data not shown) . Thus, the increased density of staining below the major silver-
stained band in Fig. 2 (5.4 kD at 0 h, -4.9 kD at 1-4 h, see arrows) probably is
a result of two closely migrating bands that are unresolved in this experiment and
possibly due to the higher concentration of CMP-NANA in the growth medium.
Thebinding of mAb3F11 to the 4.5-kD component (Fig . 2 B) was decreased markedly
by 2 h andwas absent by 3 h, while the binding ofmAb 1-1-M to the 5.4-kD compo-
nent (Fig . 2, C) was not negatively affected by growth in the presence ofCMP-NANA .
In contrast to the 4.5-kD component, the 5 .4-kD component exhibited an increased
binding of mAb 1-1-M seen as a diffuse band in the 3- and 4-h samples.
Effect of CMP-NANA on 4.5-kD+ (mAb 3FI1 +) and 4.5-kD- (mAb 3F11 -) Gonococcal
Strains . To determine whether the effect of CMP-NANA on LOS occurred with
other gonococcal strains, eight 3F11 + and four 3F11 - strains were grown on GC agar
containing CMP-['4C]-NANA. The results are shown in Fig. 3 . The silver stain
showed that most of the LOS samples had multiple components (Fig. 3 A) and that
the Mr of bands from 3F11" strains were lower than those of the 3F11 + strains . How-
ever, only the 3F11+ organisms incorporated any of the radioactivity, and they in-
corporated it into the 4.5-kD LOS component (Fig . 3 B, lanes 1 and 6-12) . In con-
trast, the 3F11" strains (Fig. 3, lanes 2-5) did not incorporate the radioactivity.
Although strains 15253v and 15433v are population variants of strains 15253 and
15433, both strains are designated as 3F11 - strains because they reverted from 3F11 +
to 3F11 - during passage . In a few of the 4.5-kD + LOSs, radioactivity also was in-
corporated into a higher or lower Mr component (Fig . 3 B, lanes 7, 8, and 12) .
FIGURE 3. Effect of CMP-
NANA on the LOS of gonococ-
cal strains that are 3F11' or
3F11 -. 12 strains were grown
on solid GC media in the pres-
ence of CMP-['4C]-NANA.
Proteinase K lysates were sep-
arated by SDS-PAGE and silver
stained (A). The gel was dried,
then autoradiographed. Lanes
were for (A) F62, (2) 15253, (3)
15253v, (4) 15433, (5) 15433v,
(6) DOV, (7)WR213, (8) 15254,
(9) 15255, (10) 15219, (11)
15220, and (12) 15221 . Strains
15253v and 15433v are mAb-
selected population variants of
strains 15253 and 15433, respec-
tively. The 4.5-kD component
of F62 is designated in A. The
arrow points to the components
that have radioactivity incorpo-
rated. The 3Fll' and 3F11 -
strains are indicated below B.
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IEM ofN. gonorrhoeae Stmin 1291 Grown in LiquidMedium Containing CMP-NANA . To
reveal sialylation of the LOS on individual organisms, we performed immunoelec-
tronmicroscopy on strain 1291 grown in the presence or absence of CMP-NANA .
We used mAb 06134 as the probe for the expression of the epitope before and after
sialylation . The results are shown in Fig. 4. mAb 06B4 bound circumferentially on
strain 1291 grown in the absence of CMP-NANA (Fig. 4 A), but bound minimally
to strain 1291 grown in the presence ofCMP-NANA (Fig . 4 B) . The CMP-NANA-
treated organisms (same sample as shown in Fig. 4 B) were treated with neuramini-
dase and incubated with mAb 06134, then with 15-nm colloidal gold-conjugated
anti-mouse IgM. The circumferential binding of 15-nm gold secondary antibody
(Fig . 4 C) indicated that neuraminidase treatment resulted in reexpression of the
06134 epitope.
IEM ofGonococci in Normal Human Polymorphonuclear Leukocytes (PMNs). Strain 1291,
which was positive for mAb 06B4 (and 3F11) in an in vitro binding assay (Fig. 4)
(14) was incubated with PMNs for 1 h, and the mixture was incubated sequentially
with mAb and gold-conjugated secondary antibody, neuraminidase, mAb, and sec-
FIGURE 4. Colloidal gold IEM of gonococcal strain 1291 grown in the presence and absence
ofCMP-NANA. Strain 1291 was grown in liquid GC mediawith or without CMP-NANA, treated
sequentially with mAb06B4 and colloidal gold-conjugated secondary antibody, then examined
with an electron microscope . (A) No CMP-NANA, mAb, 5-nM gold secondary antibody ; (B)
CMP-NANA,mAb, 5-nM gold secondary antibody; (C) CMP-NANA, treatment with neuramin-
idase, mAb, 15-nM gold secondary antibody ; (D) CMP-NANA, mAb, 5-nm gold secondary an-
tibody (same as B), treatment with neuraminidase, mAb, 10-nm gold secondary antibody. The
small arrow points to 5-nm gold particles (few) and the large arrow points to 10-nm gold particles
(predominate). The bar equals 1 am .
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ondary antibody with gold particles of a size larger than the first . Fig. 5 shows that
strain 1291 in PMNs only slightly bound mAb 06B4 before neuraminidase treat-
ment (Fig. 5 A, 10 nm; B, 5 nm), but showed increased binding after neuraminidase
treatment (Fig . 5 A, 5 nm; B, 10 nm). Each of two neuraminidases tested (Clostridium
perfringens and Streptococcus, see Materials and Methods) had the same effect . Some
antibody binding occurred with organisms before they were treated with neuramin-
idase, and antibody bound both to organisms inside and outside the PMNs (data
not shown), indicating that they were not completely modified during a 1-h incuba-
tion with PMNs. Neuraminidase-treated and -nontreated sections ofthe organisms
in PMNs tested with anti-H .8 (mAb 2C3) showed that anti-H .8 bound circumferen-
tially to >90% of the organisms (data not shown), indicating that blockage of the
4.5-kD LOS component was not due to a general effect on outer membrane surface
antigens .
Transfer ofSiahc Acid to LOSby a Gonococcal Detergent Extract. Therapid modification
of the LOS of strains grown in the presence of CMP-NANA (Fig. 2) indicated that
an enzymatic step may be involved . To test this hypothesis, purified LOS from N. gonor-
rhoeae strain F62 was incubated with CMP-['4C]-NANA and a detergent extract of
F62 . The results of this experiment are shown in Fig. 6. The autoradiographs of
SDS-PAGE-separated samples indicated that the extract resulted in incorporation
of the label in an LOS component that migrated at an Mr slightly above the 4.5-
FIGURE 5. IEM ofgonococcal strain 1291 incubated with human PMNs. Strain 1291 was grown
on solid GC media, then washed and prepared as described in Materials and Methods. (A) mAb
06114, 10-nm gold secondary antibody; neuraminidase, mAb, 5-nm gold secondary antibody.
(B) mAb 06114, 5-nm gold secondary antibody, neuraminidase, mAb, 10-nm gold secondary an-
tibody. The bar equals 1 tLm.
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FIGURE 6. Modification of gonococcal strain F62 LOS by a detergent
extract ofthe organism . Purified F62 LOSand CMP-[14C]-NANA were
incubated separately with and without a 0.5% Triton X-100 extract of
F62 gonococci. Samples were separated by SDS-PAGE, silver stained,
then the gel was dried and autoradiographed . (A) Silver stain ; (B) auto-
radiograph . Lanes were for (1) LOS, extract, 10-Al sample (1 Wg LOS) ;
(2) LOS, extract, 20-A1 sample (2,ug LOS) ; (3) LOS, no extract, 10-pl
sample (1 jig LOS); and (4) LOS, no extract, 20-w1 sample (2 Wg LOS) .
For samples tested without extract, all other reagents were added except
the extract. The arrows in A point to the position of the silver stained
band that is radioactive .
kD LOS component (Fig . 6, lanes 1 and 2). Negative control samples containing
all reagents, except the extract, did not incorporate CMP-NANA (Fig . 6, lanes 3
and 4) . These results suggested that strain F62 has a STase that catalyzes the transfer
of sialic acid to LOS .
Transfer ofSialic Acid to LOS by a2,3 andu2,6 STase. The immunochemical similarity
between structures on human glycoconjugates and on the 4.5-kD component of
gonococcal LOS suggested that the LOS might act as an acceptor for mammalin
STase specific for terminal (3-Gal or Galg1-4G1cNAc. To test this hypothesis, purified
LOS from N. gonorrhoeae strain F62 was incubated with CMP-[ I4C]-NANA and ei-
ther rat liver CMP-NANA:Gal01-4G1cNAca2->6 STase or porcine submaxillary
gland C MP-NANA:OGala2-3 STase . The autoradiographs of the SDS-PAGE-sep-
arated samples (Fig . 7) indicated that the two STases acted on different LOS compo-
nents . Treatment of F62 LOS with a2-6 STase resulted in the label being incorpo-
rated in a component that migrated slightly below the predominate low M,
component of F62 LOS (Fig. 7, 2-6ST), while treatment with the a2-3 STase resulted
in the incorporation of label into a component that migrated at the top of the high
Mr component (Fig . 7, 2-3ST) . As a positive control, asialofetuin was used in place
of LOS as acceptor, and the presence of radioactivity in the SDS-PAGE-separated
protein confirmed that the two enzymes were active (data not shown) . The silver-
stained components of F62 LOS after enzyme treatment appeared identical to the
nontreated components (Fig. 7, lanes 1 and 2) . These results indicated that, although
some radioactivity was incorporated in F62 LOS, only partial modification of the
components occurred .
Activity ofAnti-sialic Acid mAbs with CMP-NANA-treated LOS. Because of the ac-
tivity of mammalian STases with LOS and the immunochemical similarity of epi-
topes on LOS and human glycosphingolipids, we tested strain F62 grown in the pres-
ence and absence of CMP-NANA with mAbs that recognize sialylated structures
(tx2-"3- and a2->6-Gal-R) on mammalian glycosphingolipids and glycoproteins . Al-
though the mAb 3F11-defined epitope was blocked (>95% reduction in counts) by
the CMP-NANA treatment, indicating significant incorporation ofsialic acid in the
LOS, none of the anti-sialic acid mAbs (H6-3C4, IB9, NUH2, MC-813-70 ; see
Materials and Methods for specificities) recognized either the CMP-NANA-treated
or -untreated F62 gonococci .
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FIGURE 7 . Modification of gonococcal strain
F62 LOS by mammalian a2-3 and a2-6
STases . Purified F62 LOS and CMP-["Cl-
NANA were incubated separately with and with-
out porcine submaxillary gland a2-3 STase or
rat kidney a2-6 STase. Samples were treated as
above (see legend, Fig. 6) . Lanes were for (1) sil-
ver stain, a2-6 STase; (2) silver stain, noenzyme ;
(3) autoradiograph, a2-6 STase; (4) autoradio-
graph, no enzyme ; (5) autoradiograph, a2-3
STase; (6) autoradiograph, no enzyme . For sam-
ples tested without enzyme, all other reagents were
added except enzyme. The arrows in A, lanes 1
and 2, point to the position of the silver-stained
bands that are radioactive ; the arrows in lanes 3
and 4 pointing to the same component are pro-
vided as a reference.
Discussion
Our studies demonstrate that a 4.5-kD component of gonococcal LOS is altered
when organisms are grown in the presence of CMP-NANA (Fig . 1), and that there
is a concomitant decrease in the expression of mAb-defined epitopes (Fig. 2 and
Table 1) . The results of these studies extended those of Nairn et al . (7) and Parsons
et al . (8), who showed that CMP-NANA probably is the low M, factor extracted
from human RBC that induces gonococcal resistance to killing by human serum,
and that CMP-NANA sialylates gonococcal LOS, decreasing its reaction with bacte-
ricidal antibody (42) .
With cells grown both in liquid and solid medium, the component with incorpo-
rated radioactivity was of an Mr larger than the 4.5-kD component, and the incor-
poration of radioactivity occurred only with strains having the 4.5-kD+ (3F11+) LOS,
not with strains lacking the 4.5-kD component (Figs . 1-3) . These results suggested
that the 4.5-kD component is the minimal structure required for modification by
CMP-NANA. Furthermore, the epitope recognized by the mAb is possibly the site
of sialylation . However, the levels of CMP-NANA required for blocking the 4.5-kD
LOS component (100-500 Ag/ml) are relatively high compared with the levels reported
for inducing gonococci to serum resistance (5 x 10 7 serum-sensitive gonococci in-
duced to serum resistance in defined medium containing -12.3 Itg CMP-NANA)
(8) . The difference in concentrations may be due to our use of a nondefined medium
for CMP-NANA treatment and/or to slightly higher concentrations of organisms
(10) in the liquid medium . In subsequent studies, we have used lower concentra-
tions of inoculum in lower concentrations of CMP-NANA and retained blockage
of the 4.5-kD epitope (data not shown) .
Cold particle IEM studies with mAb 06134 and gonococci in human PMNs were
suggestive that modification of the 4.5-kD LOS component by addition of sialic acid
may occur in vivo (Fig . 5) . For gonococci incubated with PMNs, a 1-h incubation
was sufficient to modify binding of mAb. In subsequent experiments, we have noted
that even a 10-min incubation resulted in a 60-90% decrease in mAb 06114 binding
(data not shown), indicating this was a rapid process . Since we could not detect which
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organisms previously had been inside aPMN during processing, we could not make
any conclusions by IEM regarding differences in 3F11 epitope expression (and sialy-
lation of the 4.5-kD component) on organisms inside or outside the PMNs. These
results are supported by experiments with gonococci in human urethral exudates
where we found little reaction of the urethral gonococci with mAb 06134 before neur-
aminidase treatment, but, similar to the experiments with CMP-NANA in vitro (Fig.
4), there was an increased binding of the mAb after treatment (43) . These results
are relevant in two respects . Gonorrhoea is an inflammatory disease, so many PMNs
are found in urethral exudates, and PMNs have been shown to contain high resistance-
inducing activity (4) that maybe due to CMP-NANA or a related compound . Again,
the binding of mAb 06134 to the gonococci was decreased after incubation for 1 h
with the PMNs and restored by treatment with neuraminidase (Fig. 5) .
Using Salmonella rough mutant LPSs of known structure as our reference (10), we
estimated the shift in theMr ofthe 4.5-kD component of 1291 and F62 (Figs. 1 and
2) to be -400 daltons. This suggests that the newly expressed 4.9-kD LOS compo-
nent ofthese strains has at least one sialic acid residue present. In addition, the loss
ofepitope expression on CMP-NANA-treated gonococci could be reversed if the or-
ganisms were treated with neuraminidase (Table I and Fig. 4), suggesting that the
alteration in epitope expression was due to the addition of sialic acid, as concluded
from other studies (42) . However, the silver-stain pattern of the higher Mr compo-
nent of F62 LOS at hours 3 and 4 (Fig. 2 A) did not correspond with the pattern
of 1-1-M binding at these time points (Fig. 2 C) . Some possible explanations for these
results are: (a) a 5.4-kD component negative formAb 1-1-M incorporates some CMP-
NANA when CMP-NANA is present in high concentrations (500 kg/ml) ; (b) a 5.4-
kD- and 1-1-M-positive component incorporates CMP-NANA, but sialylation does
not block 1-1-M binding as it does for the 06134 epitope on the 4.5-kD component;
(c) some 4.5-kD components polysialylated in high concentrations of CMP-NANA
migrate at an Mr of 5.4 kD. Each of these cases could account for the presence of
a component that does not stain well with silver and is altered in migration, but
not in binding of 1-1-M.
The relative stability of 1-1-M epitope expression on CMP-NANA-treated gono-
cocci (Table I, Fig. 2) indicates that the higher Mr LOS component of F62 does not
possess the terminal sugar needed for modification by CMP-NANA. Chemical analysis
of the oligosaccharide components of F62 LOS by liquid secondary ion mass spec-
troscopy has revealed that, except for an additional sugar on their nonreducing end,
the higher and lower Mr components of F62 LOS are similar, if not identical, and
the terminal sugar on the nonreducing end of the longest branch of these 4.5-kD,
lower Mr molecules is galactose (44) . If modification of the 4.5-kD component by
CMP-NANA is dependent on the terminal sugar at the nonreducing end of the
molecule, then the additional sugar on the higher Mr component may prevent
modification .
The data presented so far suggest that gonococcal strains have STase that is active
with exogenous CMP-NANA, although, as yet, no STase has been purified . How-
ever, detergent extracts of strain F62 were able to transfer label from CMP-[ 14C]-
NANA into a component of F62 LOS that migrated at a slightly higher Mr than
the 4.5-kD component (Fig. 6) . This result shows that the purified LOS can act as
acceptor for sialic acid and that viable gonococci are not necessary for sialylation
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to occur. Rat and pig STases also were able to use F62 LOS as an acceptor, but
they incorporated radioactivity from CMP-NANA into different locations in the LOS,
and <10% of the total label added to the reaction mixture was incorporated (Fig .
7) . The later results may be due to the use of STases from species other than human.
For example, STases are present in human cervical epithelium (45, 46) and human
seminal plasma (47), and they vary in activity depending on the hormonal state
(46) or sperm concentration (47) . In future studies it will be important to locate
where the putative gonococcal STase activity resides (inner or outer membrane, in-
tracytoplasmic), whether human STases can modify gonococcal LOS, and whether
these STases have any role in vivo .
The phenotypic conversion (sialylation of LOS) of in vitro grown organisms after
their incubation with in vivo substances (CMP-NANA) (7, 42) may be one explana-
tion for the paradox of organisms having in vitro sensitivity to the serum in which
they caused infection (48) . Since the 4.5-kD component of gonococcal LOSwas the
only outer membrane molecule that showed any change with CMP-NANA (Fig.
2), it is likely that it is associated with the lysis of serum-sensitive gonococci . It should
be noted, however, that many serum-resistant strains also have the 4.5-kD compo-
nent (and bind mAb 3F11) (10, 11, 14), indicating other, unidentified factors may
be involved in the shift to serum resistance .
Although the presence of sialic acid in LOS has not been directly measured, a
number of observations support this conclusion : (a) the NANA moiety of CMP-
NANA is incorporated into LOS (7, 8) (Figs . 1 and 2) ; (b) growth of organisms in
media containing CMP-NANA results in an increase in the M, of the LOS, a re-
sult less likely to occur ifmodification ofLOS is due simply to incorporation ofsugars
already part of the LOS(e.g ., N-acetylglucosamine, N-acetylgalactosamine (49, 50);
(c) the LOScomponent modified by CMP-NANA is sensitive to neuraminidase (Table
I and Figs . 4 and 5) with a concurrent restoration to serum sensitivity (42) ; and
(d) gonococcal detergent extracts and mammalian STases can use gonococcal LOS
as acceptors with CMP-NANA (Figs . 6 and 7) .
The biologic functions described for sialic acid most relevant to gonococcal patho-
genesis are those of recognition and antirecognition (51-53). In future studies of
LOS sialylation, we will study the effects ofsialylation on recognition ofhuman anti-
LOS antibodies and complement (52), and of galactose-specific human cell lectins
(54) that may be involved in bacterial-host cell interaction .
Summary
After growth of gonococci in the presence of cytidine monophospho-N-acetyl-
neuraminic acid (CMP-NANA), their 4.5-kD lipooligosaccharide (LOS) component
was increased by -400 daltons, whereas the LOS ofstrains lacking the 4 .5-kD com-
ponent were unaffected . Expression of mAb-defined epitopes on the 4.5-kD compo-
nent was decreased on LOS of strains grown in CMP-NANA, and treatment of the
LOS with neuraminidase reversed this affect . Gonococci incubated with human PMNs
also had decreased expression of the 4.5-kD+ epitopes . A detergent extract of gono-
cocci incorporated radiolabeled NANA in the LOS, suggesting the presence of a sial-
yltransferase in gonococci . Exogenous sialyltransferases also could use LOS as an
acceptor.
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